Age, Gender, and Women’s Health and the Patient

Lesley A. Houghton,1,2 Margaret Heitkemper,3 Michael D. Crowell,4 Anton Emmanuel,5 Albena Halpert,6 James A. McRoberts,7 and Brenda Toner8

Patients with functional gastrointestinal disorders (FGIDs) often experience distress, reduced quality of life, a perceived lack of validation, and an unsatisfactory experience with health care providers. A health care provider can provide the patient with a framework in which to understand and legitimize their symptoms, remove self-doubt or blame, and identify factors that contribute to symptoms that the patient can influence or control. This framework is implemented with the consideration of important factors that impact FGIDs, such as gender, age, society, and the patient’s perspective. Although the majority of FGIDs, including globus, rumination syndrome, irritable bowel syndrome, bloating, constipation, functional abdominal pain, sphincter of Oddi dyskinesia, pelvic floor dysfunction, and extraintestinal manifestations, are more prevalent in women than in men, functional chest pain, dyspepsia, vomiting, and anorectal pain do not appear to vary by gender. Studies have suggested sex differences in somatic, but not visceral, pain perception, motility, and central processing of visceral pain; although further research is required in autonomic nervous system dysfunction, genetics, and immunologic/microbiome. Gender differences in response to psychological treatments, antidepressants, fiber, probiotics, and anticholinergics have not been studied adequately. However, a greater clinical response to 5-HT3 antagonists but not 5-HT4 agonists has been reported in women compared with men.

Keywords: Sex; Development; Society; Symptoms.

This review discusses the patient’s perspective and biological basis for sex and gender differences in functional gastrointestinal disorders (FGIDs). Attention is given to the lived experience of irritable bowel syndrome (IBS) as well as the importance of patient interaction with the health care provider. In addition, the review highlights the current literature related to gender- and sex-based differences in visceral and somatic sensitivity, pain, motility, and the overlap of FGIDs, in particular IBS, with other chronic conditions.

The Patient Perspective

The Patient Experience of FGIDs

“IBS is very frustrating; it dominates life style and daily activities mostly through its unpredictability. You must always plan for the ‘what if’ ‘what if I eat more’ ‘what if toilet facilities are not available’ ‘what if I cannot break away’. It leaves you feeling ‘dirty or unclean’ and inhibits social mixing and sexual activity. IBS is frustrating. And that’s the bottom line…” IBS study participant.

For patients with chronic symptoms, the psychological and social ramifications of their illness are often more important than the physical impairment. Three over-riding themes seem to dominate the experience of living with moderate to severe FGID: (1) a sense of frustration, (2) a sense of isolation, and (3) search for a niche in the health/sick role continuum/dissatisfaction with the medical system.1–4 The effects of IBS on quality of life (QoL) often are underestimated. Patients with mild to moderate disease severity report that IBS restricts daily activities on average 73 days per year (20%); resulting in loss of work (13% of patients).5

There is often a disconnect between patients’ and physicians’ views of the IBS experience, regarding perceptions of etiology, severity, treatment approaches, and efficacy.6–8 When 1014 patients and 508 physicians used identical scales to rate IBS-related pain and discomfort, responses showed that physicians rated discomfort as significantly less severe than patients.9 Conversely, 35% of more than a 1000 IBS patients in an international survey, reported their symptoms as severe. In the same survey, to receive a treatment that would make them symptom free, patients would give up 25% of their remaining life (average, 15 y) and 14% would risk a 1 in 1000 chance of death.5 Many patients are reluctant to accept the functional diagnosis and many misconceptions, for example, that anxiety, depression, and diet cause IBS, and fear that IBS leads to cancer.7,8 Such misconceptions likely affect clinical outcomes and health care utilization.

The Patient–Health Care Provider Encounter

“The biggest problem is that no one (in the medical field) treats the whole person. I feel more like I’m going to a drug

Abbreviations used in this paper: EAL, early adverse life event; FGID, functional gastrointestinal disorders; HRT, hormone replacement therapy; 5-HT, serotonin; IBS, irritable bowel syndrome; QoL, quality of life.

Most current article

© 2016 by the AGA Institute
0016-5085/$36.00
http://dx.doi.org/10.1053/j.gastro.2016.02.017
dealers than someone that looks at the problem in its totality. As a result I have turned my attention to helping myself, and have had some degree of success. I wish doctors would listen to patients more when we talk about the symptoms and how they affect our daily lives," IBS study participant.

Only a small proportion (≈ 25%) of IBS sufferers consult physicians. However, those who do, have high health care utilization. The nature of the patient–physician relationship is complex. Factors within and outside the health care system are constantly molding patient and physician behavior. Patients feel frustrated with unsatisfactory explanations of FGIDs, which may be experienced as a denial of the legitimacy of their symptoms and perceive lack of empathy. Conversely, physician frustration and dissatisfaction related to treating patients with FGIDs stem from a lack of understanding of the disease, limited treatment options, limited training in communication skills, increased workload, and the perception of personality characteristics of patients with IBS with psychiatric comorbidities. Gastroenterologists perceive that patients with IBS require longer visits despite not being as sick as patients with other disorders that they manage and can show gender bias. Negative attitudes toward patients with IBS may form a barrier to objective patient assessment and effective physician–patient relationship building, and ultimately negatively impact clinical outcome. Effective communication skills can be learned and practiced and, importantly, do not increase the encounter time. Rather, effective communication skills make the process of assessment and diagnosis more efficient, improve clinical outcomes, and increase physician job satisfaction.

IBS can be challenging for both the physician and the patient. Patients must learn to self-manage a condition that can have a profound impact on everyday life. Health care providers can help by eliciting and addressing patient concerns; by offering a positive diagnosis and clear, understandable, and legitimizing explanations of the disorder; show empathy; and enter into a meaningful partnership that helps individuals replace feelings of helplessness with means of empowerment.

Gender

Sex refers to the biological make-up of the individual’s reproductive anatomy whereas gender refers to an individual’s lifestyle or personal identity. Often, these terms are used interchangeably. In this article we use sex to describe what is known about biological differences between males and females and gender to refer to what is known about behavior between men and women.

The literature on gender and health has discussed the detrimental impact of adherence to some traditional feminine gender roles on women’s health and well-being. These include gender-related expectations, such as societal standards for attractiveness; social norms regarding women’s caretaking role in relationships; and sanctions against anger expression by women. The messages women receive about gender-related expectations and the societal consequences of not measuring up to these expectations can have health consequences. There are several common gender role concerns among women with IBS including shame and bodily functions, bloating and physical appearance, and pleasing others, assertion, and anger.

One central theme that women with IBS commonly report is feelings of shame associated with losing control of bodily functions. Women are taught that bodily functions are something to be kept private and secret. One important implication of such teachings is that bowel functioning becomes a source of shame and embarrassment more so than it does for men.

The finding that women often score higher on indices of bloating and constipation also can be discussed as a gender-related theme. Society’s focus on how women look (eg, thinness as a necessary standard of attractiveness) can lead women to experience bloating not only as a source of physical discomfort, but of psychological distress as well. The physical and psychological distress that women may experience with abdominal discomfort, coupled with the perception that their pain is being minimized or trivialized by health care professionals, may lead women to respond by becoming more hypervigilant to any sign of pain or discomfort.

Women as compared with men are socialized to please others, often at the expense of their own needs. Women who express anger, make demands, or question authority are often given the label of being hysterical, have their complaints dismissed, or have their femininity called into question. Potential repercussions for women who express their own wants and needs often are sufficient to keep women silent. These social expectations of women can lead to the silencing of certain thoughts, feelings, and behaviors rather than jeopardize relationships that are in place.

A study that compared women with IBS with women with inflammatory bowel disease found that women with IBS score higher on measures of self-silencing than inflammatory bowel disease patients. In another study, women reported shame in not living up to gender norm expectations for women in domains of relationships (taking care of others at the expense of their own needs), attractiveness (caused by bloating), and lack of desire to engage in sex (caused by IBS symptoms). Men in this study focused more on IBS symptoms impacting their paid employment and sense of control. They also found that in interactions with health care providers, women risked being trivialized and men risked being overlooked because IBS may be labeled as a women’s health concern.

Gender and Social Factors

It is important to acknowledge that health and illness occur within a larger social context. The meaning and expression of illness occur against a complex backdrop of a multitude of social determinants of health. The social determinants that have been investigated in FGIDs include life stressors; history of sexual, physical, and emotional abuse; and early life experiences including gender role socialization, social support, and social factors as assessed by QoL scales.
There have been limited studies to date that have assessed gender differences in life stress related to FGIDs.\textsuperscript{23} Although the data support a significant role for life stress in IBS, future studies will need to determine whether there are differences in the relationship between stress and FGIDs in women and men. Although stress affects the gut in most people, patients with IBS appear to experience greater reactivity to a variety of stressors.

One form of social stress that has received attention in the study of FGIDs is sexual, physical, or emotional abuse.\textsuperscript{24–28} However, most work in this area has included only women or a female-predominate sample. Because of conflicts in the literature, more research is needed to determine whether there are gender differences in history of abuse in FGIDs.

Studies also have investigated whether women and men with FGIDs differ on health-related QoL measures.\textsuperscript{29} For example, in a study of referral center and primary care patients, Simren et al\textsuperscript{30} found that women with IBS reported a lower QoL compared with men with IBS. Similar results were found in a Chinese outpatient population.\textsuperscript{29} Dancey et al\textsuperscript{31} found that men and women with IBS reported similar QoL scores, as well as similar levels of symptom severity, perceived stigma, and illness intrusiveness. However, these investigators also found gender differences in the relationship among these variables. For example, among women, IBS symptom severity exerted a significant impact on QoL, whereas for men, the psychosocial impact of illness intrusiveness was greater in every domain except sexual relations. The authors suggest that these results have implications for how socialization shapes IBS-related gender differences.

### Gender and Epidemiology

Most individuals with FGIDs do not seek health care and the decision to seek care introduces bias in research. This section focuses on population-based research, which is used to fully evaluate the epidemiology and clinical symptoms in these individuals. The proposal that FGIDs may be more prevalent in women stems from a variety of sources reviewed elsewhere: studies documenting a greater prevalence of FGIDs with other chronic pain conditions that are more common in women (fibromyalgia, chronic pelvic pain), studies proposing an effect of the menstrual cycle on symptom severity, and studies suggesting that particular agents are more effective in women.

#### Functional Esophageal Disorders

Functional esophageal disorders are common.\textsuperscript{32} Globus sensation and rumination syndrome are reported by approximately 1 in 10 of the population,\textsuperscript{32–35} and are more common in women. Men with globus tend to have greater levels of somatization and depression.\textsuperscript{33} The prevalence estimates of functional chest pain, based on self-report, vary between 12.5% and 25%,\textsuperscript{32,36} with an equal gender prevalence in the general population.\textsuperscript{12} There is a higher female-to-male ratio in tertiary care referral centers,\textsuperscript{37} and women tend to use terms such as “burning” and “frightening” more than men.\textsuperscript{38} The challenge in research studies of functional esophageal disorders is identifying those individuals who predominantly have a functional esophageal disorder rather than gastroesophageal reflux disease, which is not associated with gender difference in rates or reflux symptoms.

#### Functional Gastroduodenal Disorders

Functional dyspepsia affects 15%–20% of the general population\textsuperscript{39} and does not vary with gender.\textsuperscript{39–41} Being a woman was a significant predictor of functional dyspepsia when compared with organic causes of dyspepsia.\textsuperscript{42} Although females have physiological evidence of delayed gastric emptying, there is little relationship between these measures and symptom severity or hormonal status.\textsuperscript{43,44} Adolescent girls are twice as likely to report aerophagia as

### Table 1. Gender Differences of History of Sexual, Physical, and Emotional Abuse in Persons With and Without IBS

<table>
<thead>
<tr>
<th>Reference</th>
<th>Early life events</th>
<th>Findings</th>
<th>Gender differences within group comparisons</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>Childhood abuse, sexual abuse</td>
<td>A history of sexual abuse was more common in women than in men, but the investigators did not differentiate between patients with or without IBS</td>
<td>Not addressed</td>
</tr>
<tr>
<td>26</td>
<td>Severe lifetime sexual trauma, severe childhood sexual abuse, lifetime sexual victimization</td>
<td>All of the IBS patients studied who reported a history of sexual abuse were female</td>
<td>Women &gt; men</td>
</tr>
<tr>
<td>24</td>
<td>General trauma, physical punishment, emotional abuse, and sexual events</td>
<td>Significant differences were observed mainly in women with IBS; various types of early adverse life events were associated with the development of IBS, particularly among women</td>
<td>Women &gt; men</td>
</tr>
<tr>
<td>27</td>
<td>Childhood abuse</td>
<td>No significant association of childhood adversity with the likelihood of developing IBS in either men or women</td>
<td>No differences</td>
</tr>
<tr>
<td>28</td>
<td>Childhood abuse</td>
<td>A history of child abuse was similar in case and control groups, but the investigators did not differentiate between patients with or without IBS</td>
<td>Not addressed</td>
</tr>
</tbody>
</table>
adolescent boys. The overall prevalence of functional vomiting is 2.3%, and there is no association with gender.

**Functional Bowel Disorders**

Female-to-male ratios of IBS vary widely geographically, from 3:1 in urbanized Western populations to 1:1 in Nigeria (Figure 1 and Table 2), but overall the prevalence of IBS internationally is 67% higher in women than in men (odds ratio, 1.67; confidence interval, 1.53–1.82).

In terms of symptom severity, among patients with mild symptoms (<3 Manning criteria), 65% were women, increasing to 80% in those with more severe symptoms (≥3 criteria). Women have a more impaired QoL with IBS, with the somatic symptoms correlated to a gender-related increased prevalence of anxiety and depression.

There is a greater women-to-men predominance in non-pain-associated symptoms of constipation, bloating, and extraintestinal manifestations. Women are twice as likely as men to report bloating or abdominal distention. Abdominal pain scores for men and women with IBS are similar; however, men report more diarrhea and women report more constipation. In addition, women with IBS were more likely to report bloating and nausea as well as extraintestinal symptoms compared with men. There is an amplification of GI symptoms during the late luteal and early menses phases.

The female-to-male ratio for constipation is increased for both the outlet-type (poor pelvic muscle tone) and the combined IBS + outlet-type of functional constipation. Women with functional constipation were 2 times more likely to seek medical care compared with men. As with most FGIDs, the prevalence of functional constipation and IBS constipation is lower in Asian populations, but the female preponderance is similar to Western populations.

Functional abdominal pain is much more common in children and adolescents than adults, and the rate of diagnosis is higher in girls than in boys.

**Functional Disorders of the Biliary Tract and Pancreas**

The prevalence of sphincter of Oddi dyskinesia is 0.8%, and is 4–5 times more common in women.

**Functional Anorectal Disorders**

Prevalence rates of fecal incontinence vary from 2% to 11%. Among nursing home residents, incontinence is more common in men, in contrast to older people living at home. There is no difference in gender in functional anorectal pain. Pelvic floor failure is common and increases with age, and is more common in women.

**Gender and Overlapping Functional Disorders**

Patients with FGIDs often report other physical and mental comorbidities (ie, extraintestinal conditions). Co-morbid conditions reported by IBS patients include fibromyalgia, migraine headache, joint hypermobility syndrome, temporomandibular joint disorder, bladder pain syndrome/interstitial cystitis, anxiety, and depression. All of these conditions have a female predominance in the general population and many have a pain component.

Among women with FGIDs a number of female-specific conditions are more common when compared with non-FGID groups. These include dysmenorrhea, endometriosis, adenomyosis, leiomyomas, pelvic floor myalgia, vulvodynia, chronic cyclic pelvic pain, dyspareunia, dysmenorrhea, and polycystic ovary syndrome. Dyspareunia and sexual functioning in women with IBS remain understudied problems.
Table 2. The Effect of Sex and Age on the Prevalence of FGID

<table>
<thead>
<tr>
<th>FGID</th>
<th>Effect of sex</th>
<th>References for sex</th>
<th>Change with age</th>
<th>References for age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esophageal Globus</td>
<td>F &gt; M</td>
<td>32</td>
<td>↓</td>
<td>32,49</td>
</tr>
<tr>
<td>Rummation</td>
<td>F = M</td>
<td>32</td>
<td>↓</td>
<td>32</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>34,35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional chest pain</td>
<td>F = M</td>
<td>49</td>
<td>↓</td>
<td>32,49</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>36,50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional heartburn</td>
<td>F &gt; M</td>
<td>49</td>
<td>=</td>
<td>32</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>F &gt; M</td>
<td>32</td>
<td>↑</td>
<td>32</td>
</tr>
<tr>
<td>Gastroduodenal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>F = M</td>
<td>32</td>
<td>↓</td>
<td>52</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>39,40,53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aerophagia</td>
<td>M &gt; F</td>
<td>32</td>
<td>↑</td>
<td>32</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional vomiting</td>
<td>F = M</td>
<td>46</td>
<td>↓</td>
<td>46</td>
</tr>
<tr>
<td>Biliary tract</td>
<td>F &gt; M</td>
<td>32</td>
<td>↑</td>
<td>32</td>
</tr>
<tr>
<td>Lower GI tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBS</td>
<td>F &gt; M</td>
<td>56</td>
<td>↓</td>
<td>32</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>32,46,65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional constipation</td>
<td>F &gt; M</td>
<td>56</td>
<td>↑</td>
<td>63</td>
</tr>
<tr>
<td>M &gt; F</td>
<td>32,48,62</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional diarrhea</td>
<td>M &gt; F</td>
<td>32</td>
<td>↓</td>
<td>46</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>46,60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional bloating</td>
<td>Discordant</td>
<td>32</td>
<td></td>
<td>32</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>66,67</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAPS</td>
<td>F &gt; M</td>
<td>32</td>
<td>↓</td>
<td>32</td>
</tr>
<tr>
<td>F &gt; M</td>
<td>68</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fecal incontinence</td>
<td>F &gt; M (at home)</td>
<td>69</td>
<td>↑</td>
<td>70</td>
</tr>
<tr>
<td>M &gt; F (nursing homes)</td>
<td></td>
<td>71</td>
<td></td>
<td>64</td>
</tr>
<tr>
<td>Functional anorectal pain</td>
<td>F &gt; M</td>
<td>32</td>
<td>↓</td>
<td>32</td>
</tr>
<tr>
<td>Outlet delay</td>
<td>F &gt; M</td>
<td>72</td>
<td>=</td>
<td>72</td>
</tr>
</tbody>
</table>

FAPS, functional abdominal pain syndrome.
Hysterectomy is 3-fold higher in women with IBS, suggesting that the overlap with gynecologic conditions may contribute to greater health care seeking and subsequent surgical intervention.

Several mechanisms may account for the comorbidity in women with FGIDs, particularly IBS. These include brain activation patterns, dysregulation of the hypothalamic–pituitary–adrenal axis, immune dysfunction, visceral and somatic pain sensitivity alterations, autonomic nervous system dysregulation, and genetic susceptibility. Because the etiology and pathophysiology of each of these conditions likely are complex and multifactorial, a single common pathogenesis has remained elusive. Other factors, including access to health care and health care–seeking behavior, also may contribute to gender differences in the diagnosis of comorbid conditions. The type, number, and duration of comorbid conditions may contribute to the toll of interpersonal stress.

**Gender and Pathophysiology**

**Preclinical**

**Visceral pain perception.** Under basal conditions, most studies have found that normal cycling females have a greater response than males to visceral pain stimuli. Genetic background clearly has a role because the strain of rodent determines which sex is more sensitive to noxious visceral stimuli. Visceral pain can be enhanced by chemical irritation, inflammation, and stress. Generally, all of these insults either show no sex difference or greater pain responses in female animals than males. Stress, particularly repeated stress and early life stress, also produces visceral hyperalgesia days or even months after the stress period, with female rodents being significantly more susceptible.

The role of sex hormones in visceral pain has received considerable attention and produced much controversy. Studying natural variations in sex hormones in female rodents is complicated by a much shorter (4–6 days) estrus cycle, with smaller changes in the plasma estrogen and progesterone levels than in women. Because studies evaluating the effect of the estrus cycle in rodents have produced conflicting results, many investigators have resorted to ovariectomizing female rodents and comparing the effect of estrogen and progesterone replacement. This strategy also has resulted in conflicting observations that probably result from the time between ovariectomy and pain testing, the dose of estrogen/progesterone, and whether it was administered abruptly with a single dose or at a slow constant rate. The fact that estrogens can act rapidly by binding to estrogen receptors located in the plasma membrane, in addition to their slow effects mediated by gene expression, may explain some of these differences.

**Somatic pain perception.** A great deal more preclinical work has been performed on sex differences in somatic pain in animals, with more equivocal results than visceral pain. Sex differences, if found at all, depend on the specific modality being tested (thermal, mechanical, chemical, electrical), the location or dermatome involved, and the experimental model (acute, neuropathic, ischemic, inflammatory pain). Again genetic background seems to play an important role in determining which sex is more sensitive because different strains of mice and rats can produce opposite effects using the same pain test. The role of specific receptors and gene polymorphisms in sex-specific visceral and somatic pain responses is accumulating.

**Motility and permeability.** Both estrogen and to a lesser extent progesterone affect GI motility and colonic permeability. Treatment of ovariectomized rats with a combination of estrogen and progesterone results in slower colonic transit, possibly mediated by effects on nitric oxide–containing neurons in the myenteric plexus and the number and function of mast cells in GI mucosa. In addition, stress has a greater effect on decreasing upper GI motility and increasing lower GI motility in female compared with male animals. This effect likely is mediated by corticotropin-releasing factor receptor-1, which is potentiated by estrogen and expressed by colonic myenteric neurons. Estrogen also contributes to the maintenance of the intestinal barrier that serves an important role in the body’s defense against pathogens. The positive role of estrogen in maintaining intestinal barrier function may be through maintenance of tight junctions and/or influence on inflammatory response.

**Clinical**

**Abdominal symptoms.** In the general population, women are more likely to report abdominal pain and pain-related IBS diagnostic symptoms (eg, pain relieved by defecation), whereas in the IBS population, the prevalence of pain-related symptoms does not vary by gender. In addition, women with IBS report more constipation, straining, bloating, and abdominal distention, and men with IBS report more diarrhea-related symptoms, including increased stool frequency.

**Visceral pain perception.** There are no conclusive data to suggest that gender influences visceral pain perception or the referral of pain to GI stimulation in healthy and FGID subjects. Women, however, are more likely to show increased sensitivity after repetitive sigmoid distention than men with IBS. Reasons for inconsistencies across studies may include study design, small subject numbers and techniques, ovarian hormone and receptor levels, and/or stress levels, mood, vigilance, and early life and social factors.

**Somatic pain perception.** Studies suggest that healthy women tend to show greater somatic pain sensitivity than men. In FGIDs, studies are scarce, with only one study in IBS suggesting that thermal sensitivity does not differ between sexes. Variability between studies is probably for similar reasons discussed for visceral pain perception.

**Motility.** Esophageal anatomy and innervation do not appear to differ significantly by gender, and only minor gender-specific differences have been reported in esophageal motor function. Slower gastric emptying rates of both solids and liquids have been shown in females.
compared with males. Postprandial proximal gastric relaxation was prolonged and perception scores increased in women compared with men. Studies have found colonic transit times to be shorter in men than women, particularly in the right colon. Using ambulatory 24-hour colonic manometry, found pressure activity in the colon of healthy women to be reduced compared with age-matched men. The phase of menstrual cycle was not controlled in these studies. There are no published nondrug studies comparing colonic motility in women and men with IBS. Anal sphincter pressures, anal pressures during maximum sphincter contraction, and volumes required to induce a desire to defecate have been reported to be lower in women.

Cardioautonomic tone. Autonomic nervous system dysfunction has been reported in patients with IBS. However, few studies have evaluated gender differences in measures of autonomic function other than GI motility in persons with IBS. Cheng et al. reported significant blunting of the autonomic nervous system response to flexible sigmoidoscopy (a visceral stressor) in patients with IBS compared with controls, and that, overall, women had higher cardiovagal tone and lower cardiosympathetic balance compared with men.

Central processing of visceral stimuli. Healthy subjects. By using functional magnetic resonance imaging, Kern et al. showed greater response to rectal distension in sensory and affective regions (dorsal anterior cingulate cortex, prefrontal cortex, and insula cortex) in females compared with males. In contrast, Berman et al. found a trend for greater activation of the insula and anterior and midcingulate cortex to rectal distension in men compared with women. A more recent functional magnetic resonance imaging study reported greater activity in the dorsolateral prefrontal cortex and middle temporal gyrus during anticipation of rectal pain, and in the cerebellum and medial frontal gyrus during painful rectal stimulation in women compared with men. Although a study using magnetoencephalography while recording cortical evoked potential to painful esophageal stimulation reported no sex difference, sex differences in brain response to esophageal pain have been observed. Despite no significant differences in psychophysiological factors known to influence brain processing, such as anxiety, personality type, autonomic response to pain, and pain perception levels and thresholds, women compared with men showed a greater decrease in amygdala activity during anticipation of esophageal pain and a greater increase in midcingulate cortex and anterior insula activity during esophageal pain. These observations were interpreted as women having greater engagement of cognitive coping strategies to the anticipation of visceral pain, and greater emotional response during actual esophageal pain.

FGID subjects. Initial brain imaging studies using rectal balloon distension in IBS patients found that male patients showed greater activation of the insula compared with female patients, as well as dorsolateral prefrontal cortex and dorsal pons/periaqueductal gray. In contrast, female IBS patients showed greater activation of the ventromedial prefrontal cortex, right anterior cingulate cortex, and left amygdala compared with male patients. These data suggest that female patients have greater activation of affective and autonomic regions, whereas male patients show a greater activation of regions in the corticolumbic pain inhibition system. A follow-up study using connectivity modeling of the same data suggested that the differences between men and women mainly are owing to differences in the effective connectivity of emotional arousal circuitry rather than visceral afferent processing circuitry (Figure 2). More recent neuroimaging studies have shown brain activity/connectivity differences between men and women, even in the absence of a noxious stimulus (eg, rectal distension). Female IBS patients have shown higher frequency power of the insula compared with male patients. Although sex differences were seen in healthy controls in the resting state, oscillatory dynamics of emotional arousal regions (amygdala and hippocampus) were exaggerated in IBS patients, mainly owing to an increased high-frequency power in female patients. Furthermore, sex differences in the resting state oscillatory dynamics of sensorimotor regions seen in healthy subjects (greater low-frequency power in men) were reversed in IBS patients, with greater low-frequency power in women. A second resting state study showed sex differences in the functional connectivity between the dorsal anterior insula and medial prefrontal cortex and prefrontal cortex with cerebellum network in men and women are similar to healthy subjects, but more enhanced. These findings may relate to females dedicating more resource allocation to interoceptive awareness, whereas males rely more on cognitive processes, with IBS placing further stress on this bias. Finally, sex differences in the impact of early adverse life events (EALs) on resting state brain connectivity has been shown in IBS patients. EAL scores were associated with greater connectivity of thalamus, insula, anterior cingulate cortex, and middle temporal gyrus with the cerebellar network in men only. The cerebellar network is involved in fear perception, motor function, and visual-motor learning, as well as physical and psychological pain. The functional consequences of these sex-specific alterations in cerebellar network alterations remain unknown.

Sex differences in structural changes of the brain in patients with IBS also have been shown. Female patients have shown significantly less cortical thickness in the right subgenual anterior cingulate cortex than male patients. Moreover, using diffusion tensor imaging, reduced integrity of sensorimotor and descending pain modulation pathways has been shown in female compared with male IBS patients. Such differences were not seen in healthy subjects.

Genetics and immunologic/microbiome. Multiple factors including genetics, the environment, sex hormones, and the gut microbiota may modulate the immunologic response to inflammation and infection. Our understanding of the role of inflammatory factors in FGIDs and genetics, especially IBS, is increasing rapidly. The use of newomics approaches will need to consider sex as a potential factor in terms of understanding new metabolomics and
transcriptomics findings. Further research is needed to clarify the potential relevance of these factors in immune system dysregulation and FGIDs.

Emerging evidence suggests that interactions between gut microbiota and altered immune function may play a role in the pathogenesis of IBS, and several studies have supported the importance of immune activation in the pathophysiology of postinfectious IBS.139 Female gender in both adults and children has been reported as a risk factor for developing IBS symptoms after infectious gastroenteritis.140,141 The gut bacteria are modulated by sex steroid hormones, in particular estrogen. In addition, gut bacteria can influence the metabolism of estrogen (Figure 3).142 Flak et al143 proposed the concept of “microgenderome,” the bidirectional interaction between sex hormones and the microbiota.

Gender and Treatment Response

Clinical Assessment

The clinical implications of gender are relevant in both the diagnosis and clinical management of FGIDs. Beginning with the history, IBS-like symptoms often are present in gynecologic conditions, the most serious of which are ovarian and endometrial cancer, and should be included in the initial differential diagnosis. Asking the patient when symptoms started may provide important information about etiology and subsequent approaches to management. There are history and examination features unique to women: menstrual history, gynecologic surgery, and bimanual pelvic examination. The comorbidity of IBS with gynecologic pain conditions and pelvic floor dysfunction warrants careful examination. In the differential diagnosis, clinicians should avoid mistakenly using the gender prevalence to influence a premature diagnosis of a FGID.

Psychological Treatment

Whether gender makes a difference to outcomes with psychological therapy is unclear because women outnumber men in most FGID treatment trials.144 These trials have not been powered sufficiently or included subanalyses to determine whether or not there is a differential response to treatment between genders.145,146

There is no gender bias in outcomes with cognitive behavioral therapy, psychological therapy, or emotional awareness training for IBS,147 and gender was not selected into a predictive model of treatment response. By contrast,
Guthrie et al\textsuperscript{148} reported minor advantages for women in response to therapy compared with men, but gender was not selected in their final analysis model. For individual psychotherapy in patients with functional dyspepsia and severe IBS,\textsuperscript{149} efficacy is similar to selective serotonin re-uptake inhibitor therapy with no gender difference in outcome with either treatment.

Two evaluations of hypnotherapy\textsuperscript{150,151} provided contrasting results with respect to gender. An audit of 1000 IBS patients who met Rome II criteria (80\% female) for IBS and underwent hypnotherapy for 3 months found that 80\% of women improved compared with 62\% of men.\textsuperscript{151} A study of 250 participants noted a poor response in men with IBS with diarrhea.\textsuperscript{150} By contrast, a randomized controlled trial,\textsuperscript{151} albeit in a smaller population, showed that gender, age, disease duration, and IBS type had no influence on the long-term success of hypnotherapy.

**Pharmacologic Treatment**

**Psychotropic agents.** A recent systematic review of antidepressant therapy identified that most studies did not conduct separate analyses by gender.\textsuperscript{146}

**Gut-directed agents.** A number of small, variable-quality studies have been subject to meta-analysis\textsuperscript{152} and shown modest benefits over placebo for fiber, anticholinergics, and peppermint oil, but no separate analysis of gender difference was undertaken.

Therapies targeted at serotonin/5-hydroxytryptamine (5-HT) receptors in the gut seem to have a differential effect in men and women. Alosetron, a 5-HT\textsubscript{3} antagonist, provided more robust efficacy in women than men at the same dose.\textsuperscript{153} The basis for this gender difference is not clearly established. Alosetron is more effective in slowing colonic transit,\textsuperscript{154} attenuating the gastrocolonic response, and increasing rectal compliance\textsuperscript{155} in women than men.

Three large series\textsuperscript{156} of prucalopride, a highly selective 5HT\textsubscript{4} agonist, recruited 85\% female patients and showed equal efficacy in both sexes. For other drugs commonly used to treat motility disturbance (domperidone, opioid-based constipating agents, laxatives, probiotics), there is no evidence of a gender-related difference in efficacy.\textsuperscript{157}

Most medications for FGIDs are cleared through the cytochrome P450 pathway, which can be affected by female sex hormones. Although women clear drugs more quickly than men through this pathway, this is balanced by the difference in body size and adiposity of women. There have been no clinically significant differences in the pharmacokinetics of FGID drugs, and, hence, dosages need not be adapted by gender.

**Life Stages and Aging**

The FGIDs affect people across the spectrum of age. Some FGIDs increase with age whereas others decrease. Some begin in childhood whereas others start after developmental stages including puberty and menopause. The trajectory of many FGIDs are unknown owing to lack of long-term follow-up evaluation. Cohort studies with pre-identified clinical and biological markers may yield important information about the normal GI tract aging in concert with the evolution and progression of FGIDs.

Extensive epidemiologic data exist for IBS, dyspepsia, heartburn, constipation, and fecal incontinence, but less is known about the other FGIDs. The presence of FGIDs in children is well recognized. The exact age of onset of FGIDs remains to be determined. A link between childhood IBS and adult IBS remains to be established.

Both laboratory animal and human data indicate that EALs may contribute to either increased visceral sensitivity later in life and/or potentially visceral and somatic conditions.\textsuperscript{24} Although EALs result in higher rates of IBS in both genders, women appear to be more susceptible to the development of pathologies after exposure to EALs.\textsuperscript{89}

Approximately 70\%–95\% of women report heartburn, nausea, or vomiting during their pregnancies. Most episodes of heartburn occur during the first and second trimesters. Perimenopause is defined as the period of transition to menopause. In a cross-sectional study of premenopausal and postmenopausal women with IBS, there were more GI
symptoms in early postmenopausal women compared with premenopausal women.158 Menopause is the cessation of a woman’s reproductive ability. Understanding the effects of menopause on FGIDs is confounded by the effects of aging, the presence of comorbid conditions, and medication use (ie, hormone-replacement use [HRT]). In one study using the General Practice Research Database in the United Kingdom, investigators found that current and past users of HRT had an increased risk (incidence, 1.7 in nonusers and 3.8 among users) of IBS compared with nonusers.159

Overall, the prevalence of IBS decreases with age in both men and women.160 The existing literature is discordant with regard to the changes in the estimates of bloating by age.32 Most studies have found that the prevalence of constipation increases with advancing age.63,64,161 Less is known regarding functional diarrhea, although one study identified decreasing rates of diarrhea with age.46

There is some evidence to suggest that with aging there is reduced biodiversity. However, it is difficult to separate out changes that are related to aging, per se, or lifestyle, history of antibiotic treatment, hospitalization, and frailty. Reductions in fiber intake caused by poor dentition, decreased saliva production, and reduced economic resources also may contribute to age-related changes in microbiota composition.

Fecal incontinence has been studied extensively and increases with age. Data from the Nurse’s Health Study show that 4% of women age 62–87 have fecal incontinence and 7% have both urinary and bowel incontinence.162

Methodologic Issues in FGIDs

As a result of methodologic issues limiting interpretation of studies, there remain many unanswered questions concerning gender, age, and patient perspectives in FGIDs. Because of the female predominance and greater likelihood of women to participate in research studies, there are insufficient numbers of male participants to make meaningful interpretations and adequately assess gender and sex differences in psychological, physiological, and treatment studies. Given the intersection of gender and socioeconomic factors in women’s health, the environment, relationships, and resources (eg, socioeconomic status) need to be considered when assessing gender differences. Another major methodologic concern is that most studies use a cross-sectional design, which limits the more comprehensive understanding of the pathogenesis, development, course, and impact of these disorders in men and women.

Many physiologic studies use relatively small sample sizes and do not account for psychosocial variables, overlapping FGID or comorbidities, abuse history, or EALs, and, therefore, may not apply to the general patient population. These studies may be influenced by the selection bias of participants who are willing to undergo invasive research protocols.

Translating the various mechanisms of pain and GI function from animal studies to human beings is challenging. Differences in the type and strain of the animal model and type of stressor, if used, need to be taken into account when interpreting these studies.

Similarly for women, the menstrual cycle needs to be considered in studies. In most studies, menstrual phase is frequently not determined, or is assessed by the count forward/backward method and not by measuring the luteinizing hormone surge or ovarian hormone levels to assess the follicular and luteal phases more accurately. Other confounding methodologic issues include the use of oral contraceptive agents, HRT, and premenopausal vs postmenopausal status in women. The impact of the transition from a premenopausal to perimenopausal state to menopause remains unknown.

Most studies examining psychological factors have focused on anxiety and depression and, to a lesser extent, personality traits. Other aspects of psychological functioning such as quality of relationships, social support, health perceptions, traumatic and stressful events, and effects of childhood experience other than abuse largely have been ignored in studies comparing men and women.

Adequate sample sizes of each gender, particularly men, and comparable treatment doses must be obtained to determine if men and women respond similarly to treatment. There may be gender bias in the placebo response. Patients for clinical trials generally are recruited from specialty practices where women are more likely to be referred than men, thus compounding problems of selection bias.

Future studies will need to have adequate numbers of men with gender-related variables such as history of EALs, abuse, anxiety, or depression.19 At the same time, greater attention needs to be given to transgender men and women.

In summary, this review emphasizes: (1) the importance of the patient’s experience and perspective, (2) the influence of society, culture, gender, and age on all aspect of the individual’s experience, (3) the influential role of an individual’s sex on the biologic and physiologic processes of brain–gut interactions, and (4) the potential of the health care provider in influencing patient outcomes.

Supplementary Material

Note: The first 50 references associated with this article are available below in print. The remaining references accompanying this article are available online only with the electronic version of the article. To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at http://dx.doi.org/10.1053/j.gastro.2016.02.017.

References (see Supplementary References)


Reprint requests
Address requests for reprints to: Lesley A. Houghton, PhD, FRSB, FRCP, AGAF, Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32224. e-mail: Houghton.Lesley@mayo.edu; fax: (904) 953-7366.

Conflicts of interest
These authors disclose the following: Lesley Houghton has consulted over the past 12 months for GSK and Pfizer; Michael Crowell has consulted over the past 12 months for EndoStim, Inc, Medtronic, Inc, and Salix; and Albena Halpert has consulted over the past 12 months for Allergan.
Supplementary References


